AstraZeneca (AZN) Stock Rating Reaffirmed by Shore Capital

Shore Capital reiterated their hold rating on shares of AstraZeneca (LON:AZN) in a research report sent to investors on Monday, November 12th.

Several other equities research analysts have also commented on the stock. Credit Suisse Group set a GBX 6,350 ($82.97) price target on shares of AstraZeneca and gave the stock a buy rating in a report on Friday, November 9th. Deutsche Bank reissued a buy rating and issued a GBX 6,500 ($84.93) price target on shares of AstraZeneca in a report on Monday, November 12th. JPMorgan Chase & Co. reissued a buy rating on shares of AstraZeneca in a report on Friday, November 9th. Cfra set a GBX 6,200 ($81.01) price target on shares of AstraZeneca and gave the stock a neutral rating in a report on Friday, November 9th. Finally, Barclays reissued a top pick rating and issued a GBX 6,800 ($88.85) price target on shares of AstraZeneca in a report on Friday, November 9th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the company’s stock. AstraZeneca currently has an average rating of Hold and an average target price of GBX 5,927.44 ($77.45).

Shares of AZN traded down GBX 28 ($0.37) during trading hours on Monday, hitting GBX 5,927 ($77.45). The stock had a trading volume of 2,638,281 shares, compared to its average volume of 2,310,000. AstraZeneca has a fifty-two week low of GBX 4,260 ($55.66) and a fifty-two week high of GBX 5,520 ($72.13).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

See Also: Quiet Period

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply